$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

$rare Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023018017 Filed on May 05, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$108.3M	$100.5M	$103.3M
YoY Change	21.23%	25.72%	23.93%
Cost Of Revenue	$9.914M	$12.26M	$5.319M
YoY Change	19.88%	100.93%	51.58%
Gross Profit	$98.40M	$88.24M	$98.03M
YoY Change	21.37%	19.51%	22.72%
Gross Profit Margin	90.85%	87.8%	94.85%
Selling, General & Admin	$81.40M	$76.65M	$72.85M
YoY Change	19.47%	13.87%	22.58%
% of Gross Profit	82.73%	86.86%	74.31%
Research & Development	$164.9M	$165.7M	$170.8M
YoY Change	6.74%	15.75%	38.85%
% of Gross Profit	167.64%	187.78%	174.24%
Depreciation & Amortization	$5.361M	$5.236M	$4.957M
YoY Change	19.64%	28.08%	40.27%
% of Gross Profit	5.45%	5.93%	5.06%
Operating Expenses	$246.4M	$242.3M	$243.7M
YoY Change	10.64%	15.15%	33.55%
Operating Profit	-$148.0M	-$154.1M	-$145.6M
YoY Change	4.49%	12.79%	41.99%
Interest Expense	$6.225M	$5.956M	$8.038M
YoY Change	-167.04%	-167.41%	-151.33%
% of Operating Profit
Other Income/Expense, Net	-$17.36M	$308.0K	-$15.69M
YoY Change	1767.1%	6.57%	272.43%
Pretax Income	-$159.1M	-$163.5M	-$153.3M
YoY Change	0.78%	7.72%	25.19%
Income Tax	$732.0K	$495.0K	-$1.451M
% Of Pretax Income
Net Earnings	-$159.8M	-$164.0M	-$151.8M
YoY Change	1.05%	7.65%	23.99%
Net Earnings / Revenue	-147.57%	-163.16%	-146.91%
Basic Earnings Per Share	-$2.25	-$2.33
Diluted Earnings Per Share	-$2.25	-$2.33	-$2.16
COMMON SHARES
Basic Shares Outstanding	70.81M	70.22M	70.11M
Diluted Shares Outstanding	70.90M	70.37M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$552.0M	$629.4M	$747.8M
YoY Change	1.69%	5.19%	1.02%
Cash & Equivalents	$102.1M	$85.77M	$132.9M
Short-Term Investments	$449.9M	$543.6M	$614.8M
Other Short-Term Assets	$51.38M	$67.38M	$68.93M
YoY Change	-33.67%	6.91%	-3.93%
Inventory	$28.26M	$26.62M	$26.77M
Prepaid Expenses
Receivables	$70.52M	$42.99M	$40.45M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$702.1M	$766.3M	$883.9M
YoY Change	3.48%	8.31%	3.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$308.2M	$277.9M	$259.7M
YoY Change	48.62%	56.93%	83.88%
Goodwill	$44.41M	$44.41M	$44.41M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$158.2M	$159.2M	$160.1M
YoY Change	-0.6%	-0.51%	22.42%
Long-Term Investments	$71.83M	$90.41M	$154.5M
YoY Change	-59.81%	-62.5%	-47.42%
Other Assets	$26.49M	$22.26M	$16.85M
YoY Change	25.28%	4.91%	-18.06%
Total Long-Term Assets	$609.2M	$617.1M	$661.5M
YoY Change	-5.13%	-8.79%	-0.64%
TOTAL ASSETS
Total Short-Term Assets	$702.1M	$766.3M	$883.9M
Total Long-Term Assets	$609.2M	$617.1M	$661.5M
Total Assets	$1.311B	$1.383B	$1.545B
YoY Change	-0.71%	-0.05%	1.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$42.12M	$58.98M	$43.27M
YoY Change	23.1%	149.02%	152.5%
Accrued Expenses	$178.5M	$144.4M	$204.7M
YoY Change	4.8%	14.28%	40.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$244.4M	$218.2M	$261.2M
YoY Change	10.76%	30.47%	44.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$906.2M	$9.257M	$4.820M
YoY Change	23950.8%	172.91%	379.6%
Total Long-Term Liabilities	$906.2M	$9.257M	$4.820M
YoY Change	23950.8%	172.91%	379.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$244.4M	$218.2M	$261.2M
Total Long-Term Liabilities	$906.2M	$9.257M	$4.820M
Total Liabilities	$1.182B	$1.163B	$1.193B
YoY Change	84.0%	97.91%	98.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.105B	-$2.945B	-$2.781B
YoY Change	30.23%	32.3%	34.12%
Common Stock	$71.00K	$71.00K	$70.00K
YoY Change	1.43%	1.43%	1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$381.0K	$356.0K	$0.00
YoY Change
Treasury Stock Shares		$7.812K	$0.00
Shareholders Equity	$129.0M	$220.5M	$352.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.311B	$1.383B	$1.545B
YoY Change	-0.71%	-0.05%	1.51%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$159.8M	-$164.0M	-$151.8M
YoY Change	1.05%	7.65%	23.99%
Depreciation, Depletion And Amortization	$5.361M	$5.236M	$4.957M
YoY Change	19.64%	28.08%	40.27%
Cash From Operating Activities	-$116.2M	-$156.9M	-$90.34M
YoY Change	50.36%	33.48%	66.24%
INVESTING ACTIVITIES
Capital Expenditures	$16.44M	$25.03M	$26.97M
YoY Change	-153.16%	-22.22%	-268.06%
Acquisitions
YoY Change
Other Investing Activities	$115.9M	$3.951M	-$144.6M
YoY Change	5.24%	-253.26%	-269.94%
Cash From Investing Activities	$99.42M	$111.3M	-$171.6M
YoY Change	25.58%	-397.91%	-348.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	33.02M	-722.0K	1.882M
YoY Change	465.7%	-144.79%	-97.8%
NET CHANGE
Cash From Operating Activities	-116.2M	-156.9M	-90.34M
Cash From Investing Activities	99.42M	111.3M	-171.6M
Cash From Financing Activities	33.02M	-722.0K	1.882M
Net Change In Cash	16.28M	-46.07M	-260.1M
YoY Change	110.08%	-69.96%	-358.92%
FREE CASH FLOW
Cash From Operating Activities	-$116.2M	-$156.9M	-$90.34M
Capital Expenditures	$16.44M	$25.03M	$26.97M
Free Cash Flow	-$132.6M	-$181.9M	-$117.3M
YoY Change	186.18%	21.51%	206.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	543586000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	614818000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42991000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40445000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001515673
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36276
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ULTRAGENYX PHARMACEUTICAL INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2546083
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Leveroni Court
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94949
CY2023Q1	dei	City Area Code CityAreaCode	415
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	483-8800
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	RARE
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	us-gaap	Inventory Net InventoryNet	26616000
CY2022Q4	us-gaap	Inventory Net InventoryNet	26766000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	67375000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	68926000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	766336000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	883899000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	277873000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	259726000
CY2023Q1	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	5197000
CY2022Q4	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	5531000
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	85213000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	148970000
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70814462
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85768000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22949000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25961000
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159171000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160105000
CY2023Q1	us-gaap	Goodwill Goodwill	44406000
CY2022Q4	us-gaap	Goodwill Goodwill	44406000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22259000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16846000
CY2023Q1	us-gaap	Assets Assets	1383404000
CY2022Q4	us-gaap	Assets Assets	1545444000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	58981000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	43274000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	144404000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132944000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204678000
CY2023Q1	rare	Contract Liabilities Current ContractLiabilitiesCurrent	0
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79935000
CY2023Q1	rare	Cost Of Sales CostOfSales	12257000
CY2022Q1	rare	Cost Of Sales CostOfSales	6100000
CY2022Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	1479000
CY2023Q1	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11261000
CY2022Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11779000
CY2023Q1	rare	Liabilities For Sales Of Future Royalties Current LiabilitiesForSalesOfFutureRoyaltiesCurrent	3533000
CY2022Q4	rare	Liabilities For Sales Of Future Royalties Current LiabilitiesForSalesOfFutureRoyaltiesCurrent	0
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	218179000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	261210000
CY2023Q1	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	17340000
CY2022Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	19814000
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	31667000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	31667000
CY2023Q1	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	886480000
CY2022Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	875439000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9257000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4820000
CY2023Q1	us-gaap	Liabilities Liabilities	1162923000
CY2022Q4	us-gaap	Liabilities Liabilities	1192950000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70660249
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70660249
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70197297
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70197297
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	71000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	70000
CY2023Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	7812
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	356000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q1	us-gaap	Treasury Stock Deferred Employee Stock Ownership Plan TreasuryStockDeferredEmployeeStockOwnershipPlan	356000
CY2022Q4	us-gaap	Treasury Stock Deferred Employee Stock Ownership Plan TreasuryStockDeferredEmployeeStockOwnershipPlan	0
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3169371000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3140019000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3967000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6573000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2944994000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2781022000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	220481000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	352494000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1383404000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1545444000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	165698000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100496000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2994000
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1894000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	143155000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76646000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	67312000
CY2023Q1	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	254601000
CY2022Q1	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	216567000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-154105000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-136632000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6290000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	494000
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-334000
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-9329000
CY2023Q1	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	15636000
CY2022Q1	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	6584000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	308000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	289000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-163477000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-151762000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	495000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	558000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-163972000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-152320000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.33
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.33
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.19
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.19
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70368478
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70368478
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69516668
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69516668
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-163972000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-152320000
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	144000
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-60000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2462000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5090000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2606000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5150000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161366000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-157470000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	352494000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30103000
CY2023Q1	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	-750000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2606000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-163972000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	220481000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5236000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4088000
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-334000
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-9329000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29578000
CY2022Q1	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	1755000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5150000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-152320000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	796424000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-163972000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-152320000
CY2023Q1	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	31952000
CY2022Q1	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	29396000
CY2023Q1	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	0
CY2023Q1	rare	Non Cash Royalty Revenue NonCashRoyaltyRevenue	4882000
CY2022Q1	rare	Non Cash Royalty Revenue NonCashRoyaltyRevenue	4838000
CY2023Q1	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	15636000
CY2022Q1	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	6584000
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-187000
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-35000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2508000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-150000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1475000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	519000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9126000
CY2023Q1	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	-34008000
CY2022Q1	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	-16164000
CY2023Q1	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-1479000
CY2022Q1	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-3209000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-156867000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117521000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25034000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32184000
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	62024000
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	203710000
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	10715000
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	39422000
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	191598000
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	188990000
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000000
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3951000
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-120000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	111304000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37362000
CY2023Q1	rare	Payments For Proceeds From Issuance Of Common Stock Under Equity Plan PaymentsForProceedsFromIssuanceOfCommonStockUnderEquityPlan	750000
CY2022Q1	rare	Payments For Proceeds From Issuance Of Common Stock Under Equity Plan PaymentsForProceedsFromIssuanceOfCommonStockUnderEquityPlan	-1755000
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	28000
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-143000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-722000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1612000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	211000
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-108000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46074000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-153379000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	137601000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	91527000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156206000
CY2022Q1	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	132000
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	2276000
CY2023Q1	us-gaap	Inventory Net InventoryNet	26616000
CY2022Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1581000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9137000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	24782000
CY2023Q1	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	3820000
CY2022Q1	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	2101000
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Ultragenyx Pharmaceutical Inc., or the Company, is a biopharmaceutical company incorporated in Delaware.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company operates as </span><span style="font-size:10.0pt;font-family:"Calibri", sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> reportable segment and has four commercially approved products.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Crysvita® (burosumab) is approved in the United States, or U.S., the European Union, or EU, and certain other regions for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Crysvita is also approved in the U.S. and certain other regions for the treatment of fibroblast growth factor 23, or FGF23,-related hypophosphatemia in tumor-induced osteomalacia, or TIO, associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Mepsevii® (vestronidase alfa) is approved in the U.S., the EU and certain other regions, as the first medicine for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Dojolvi® (triheptanoin) is approved in the U.S. and certain other regions for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Evkeeza® (evinacumab) is approved in the U.S. and the European Economic Area, or EEA, for the treatment of homozygous familial hypercholesterolemia, or HoFH. The Company has exclusive rights to commercialize Evkeeza® (evinacumab) outside of the U.S.</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">In addition to the approved products, the Company has the following ongoing clinical development programs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX111 (formerly ABO-102) is an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">DTX401 is an adeno-associated virus 8, or AAV8, gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia, or GSDIa;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase, or OTC deficiency, the most common urea cycle disorder;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX143 (setrusumab), which is subject to the Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">’</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">s collaboration agreement with Mereo BioPharma 3, or Mereo, is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect, or OI; </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">GTX-102 is an antisense oligonucleotide, or ASO, for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX701 is an adeno-associated virus 9, or AAV9, gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">UX053 is a messenger RNA, or mRNA, product candidate designed for the treatment of patients with Glycogen Storage Disease Type III, or GSDIII, a disease caused by a glycogen debranching enzyme, or AGL, deficiency that results in glycogen accumulation in the liver and muscle.</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities. Management recognizes that the Company will likely need to raise additional capital to fully implement its business plans. Through March 31, 2023, the Company has relied primarily on its sale of equity securities, its revenues from commercial products, its sale of future royalties, and strategic collaboration arrangements to finance its operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The Company expects it will need to raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</span></p>
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, revenue recognition, and the liabilities for sales of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Calibri", sans-serif;min-width:fit-content;"> </span></p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85768000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153988000
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1964000
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	217000
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3795000
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2001000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	91527000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156206000
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11525000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9280000
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	701004000
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	884017000
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	693251000
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	723000
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3989000
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	689985000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	882363000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	407000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6135000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	876635000
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	15091000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	17486000
CY2022Q4	us-gaap	Inventory Net InventoryNet	26766000
CY2023Q1	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	42725000
CY2022Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	73558000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55796000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	78938000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	45883000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52182000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	144404000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	204678000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100496000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79935000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	100496000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79935000
CY2022Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	1479000
CY2021Q4	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	9076000
CY2023Q1	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	0
CY2022Q1	rare	Contract With Customer Liability Additions During Period ContractWithCustomerLiabilityAdditionsDuringPeriod	40000
CY2023Q1	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	1479000
CY2022Q1	rare	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	3249000
CY2023Q1	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	0
CY2022Q1	rare	Contract With Customer Assets Liability Current ContractWithCustomerAssetsLiabilityCurrent	5867000
CY2021Q4	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	351786000
CY2022	rare	Proceeds From Royalties Received Financing Activities ProceedsFromRoyaltiesReceivedFinancingActivities	490950000
CY2022	rare	Royalty Revenue RoyaltyRevenue	-21692000
CY2022	rare	Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	54395000
CY2022Q4	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	875439000
CY2023Q1	rare	Royalty Revenue RoyaltyRevenue	-4882000
CY2023Q1	rare	Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	19456000
CY2023Q1	rare	Liability For Sale Of Future Royalties LiabilityForSaleOfFutureRoyalties	890013000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31939000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29387000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12923444
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9386957
CY2023Q1	rare	Stock Issued During Period Shares At Market Offering StockIssuedDuringPeriodSharesAtMarketOffering	1050372
CY2023Q1	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	78900000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-701000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-845000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3266000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5728000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3967000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6573000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-23-018017-index-headers.html	Edgar Link	pending
0000950170-23-018017-index.html	Edgar Link	pending
0000950170-23-018017.txt	Edgar Link	pending
0000950170-23-018017-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img215925227_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rare-20230331.htm	Edgar Link	pending
rare-20230331.xsd	Edgar Link	pending
rare-ex10_1.htm	Edgar Link	pending
rare-ex10_2.htm	Edgar Link	pending
rare-ex10_3.htm	Edgar Link	pending
rare-ex31_1.htm	Edgar Link	pending
rare-ex32_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rare-20230331_def.xml	Edgar Link	unprocessable
rare-20230331_cal.xml	Edgar Link	unprocessable
rare-20230331_pre.xml	Edgar Link	unprocessable
rare-20230331_lab.xml	Edgar Link	unprocessable
rare-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

2023 Q2 Form 10-Q Financial Statement

#000095017023018017 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE Ultragenyx Pharmaceutical Inc. Stock $rare

2023 Q2 Form 10-Q Financial Statement

#000095017023018017 Filed on May 05, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare